Galectin Therapeutics Inc. GALT
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Galectin Therapeutics Inc. (GALT) is a healthcare company listed in the US with a market value of about $308M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -2646%.
About Galectin Therapeutics
Galectin Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 8% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$31M | -$47M | -$41M | -$39M | -$31M | -$23M | -$13M | -$14M | -$16M | -$21M |
| Free cash flow | — | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | $-0.48 | $-0.76 | $-0.74 | $-0.65 | $-0.52 | $-0.41 | $-0.39 | $-0.38 | $-0.49 | $-0.76 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | — | — | — | — | -2646.1% | -82.2% | -24.1% | -207.6% | — | -164.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $11.00, 261% above the current price; targets range from $11.00 to $11.00; the consensus rating is “Strong buy”; expected EPS is $-0.30 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Galectin Therapeutics pay a dividend?
Not currently.
Is Galectin Therapeutics a good stock to buy?
We do not give buy or sell advice. Galectin Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.